University Hospital Olomouc
- Address
- lock Available on a paid plan
Nephrology and Renal Cancer Research
The University Hospital Olomouc is active in nephrology and oncology, with studies focused on kidney-related diseases and renal cell carcinoma. This research is mainly aimed at testing new treatment approaches, comparing them with standard care, and improving outcomes for people with advanced kidney disease and kidney cancer.
- Advanced or metastatic renal cell carcinoma
- Clear cell renal cancer
- Primary membranous nephropathy
- Alport syndrome
Work at this site also includes studies on kidney cancer recurrence prevention and better control of proteinuria and renal function in chronic kidney disorders.
Respiratory and Pulmonary Disease Trials
Research in respiratory diseases at University Hospital Olomouc covers both common and complex lung conditions. The trials are designed to evaluate new therapies, reduce symptoms, and improve breathing capacity and long-term disease control in patients with difficult-to-treat pulmonary disorders.
- Idiopathic pulmonary fibrosis
- Progressive pulmonary fibrosis
- Severe asthma with an eosinophilic phenotype
- Oral corticosteroid dependent asthma
- Pulmonary sarcoidosis with or without extrapulmonary manifestations
- Chronic lung allograft dysfunction after lung transplantation
These studies reflect a strong focus on lung function, inflammation, and treatment effectiveness in chronic respiratory disease.
Oncology Across Solid and Blood Cancers
The site conducts broad cancer research spanning solid tumors and hematologic malignancies. Many trials aim to improve survival, delay disease progression, and refine treatment choices for patients with advanced or hard-to-treat cancers.
- Breast Cancer
- Advanced epithelial ovarian cancer
- Muscle Invasive Bladder Cancer
- Esophageal carcinoma
- Gastrointestinal stromal tumor
- Acute lymphoblastic leukemia
- Untreated Chronic Lymphocytic Leukemia
- Newly Diagnosed Multiple Myeloma
Research here includes studies of immunotherapy, targeted therapy, and combination treatment strategies to better manage advanced malignancies.
Prostate and Urologic Oncology
Clinical trials in urologic oncology at this hospital focus on prostate and bladder cancers, with an emphasis on improving disease control and reducing the risk of progression or recurrence. The goal is to evaluate whether newer treatments can offer better outcomes than current standard approaches.
- Prostate cancer
- Oligometastatic prostate cancer
- PSMA PET scan positive Castration-Resistant Prostate Cancer
- Muscle Invasive Bladder Cancer
These studies highlight the use of precision imaging and advanced cancer therapies in men’s health and urinary tract cancers.
Immune-Mediated and Transplant-Related Conditions
The research portfolio also includes immune system diseases and transplant-related complications. Trials in this area are looking at safer and more effective ways to control inflammation, preserve organ function, and improve quality of life in chronic immune-driven conditions.
- Pulmonary sarcoidosis
- Primary membranous nephropathy
- Lung transplant rejection
At University Hospital Olomouc, this work supports better management of autoimmune disease and post-transplant care through new therapeutic options.
Cardiovascular, Digestive, and Women’s Health Studies
Beyond cancer and kidney disease, the site is involved in trials across cardiovascular disease, digestive system disease, and women’s health. These studies are aimed at preventing major complications, easing symptoms, and improving day-to-day health in diverse patient groups.
- Prevention of stroke or systemic embolism in atrial fibrillation
- Esophageal carcinoma
- Sleep disturbances associated with menopause
This mix of studies shows a broad interest in preventive care, symptom relief, and treatment effectiveness across several internal medicine specialties.
Inherited and Rare Disease Research
The clinical trial program at this hospital also reaches into congenital and hereditary diseases. These studies are especially important for patients with rare conditions, where research is often needed to find more targeted and better tolerated treatment options.
- Alport syndrome
- Congenital, hereditary, and neonatal diseases and abnormalities
Research in this field is focused on improving disease control, slowing progression, and expanding treatment possibilities for uncommon disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 21 therapeutic areas and 15 of 414 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 394 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 64 by active trials.
- 1Merck Sharp & Dohme LLC14active
lock +63 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC24trials
lock +42 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Hospital Olomouc
lock Showing 1 of 259 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 414 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 40 | Unknown | 2015-11-06 | 2026-07-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.